NOTABLE LABS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.981 USD | +0.10% |
|
-0.42% | -48.10% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.98
USD
Average target price
8
USD
Spread / Average Target
+716.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.10% | 8.84M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- NTBL Stock
- News Notable Labs, Ltd.
- Vascular Biogenics : VBL Therapeutics Appoints Sam Backenroth Chief Financial Officer
